A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease

Clinical trial NCT06585449 · RECRUITING

Trial details

NCT number: NCT06585449
Sponsor: Alnylam Pharmaceuticals
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Huntington's Disease

Start date: 2024-10-14
Primary completion: 2028-07-05
Enrollment: 66

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.